Potential role of anti-idiotype antibodies in active tumor immunotherapy.
The tumor-specified cellular and humoral immunity induced by anti-idiotype antibodies (Ab2s) 2F10 and 3A4 has been studied. Ab2s were made against a monoclonal anti-L1210/GZL lymphoma, 11C1. They were screened for their ability to block 11C1 binding to tumor, induce tumor-specific DTH and CTL responses, and induce an anti-tumor humoral response. Two Ab2s, 2F10 and 3A4, which were found to have similar fine specificity and to induce similar cellular and humoral responses, were compared for their ability to elicit tumor-protective immunity. Interestingly, only preimmunization with the 2F10 Ab2 protected animals from live tumor challenge. The possible causes for this discriminatory biological effect induced by otherwise similar Ab2s are discussed.
Raychaudhuri
S
S
Department of Tumor Immunology, IDEC Pharmaceuticals Corporation, La Jolla, California.
Kohler
H
H
Saeki
Y
Y
Chen
J J
JJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000032:analysis; D000918:Antibody Specificity; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D007167:Immunotherapy; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007130:Immunoglobulin Idiotypes